Literature DB >> 11269565

Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model.

T A Puchalski1, W Krzyzanski, R A Blum, W J Jusko.   

Abstract

A mechanism-based pharmacokinetic/pharmacodynamic model was used to assess lansoprazole effects on gastric pH. The irreversible inactivation of the H+/K+-ATPase enzyme by lansoprazole controls the secretion rate of H+ ions and gastric pH values. The basal circadian rhythm of gastric acid production was taken into account as well as the effects of food intake. A model was applied to multiple-dose data from a crossover study of four dosage regimens of lansoprazole in two groups of normal male subjects. Model parameters were estimated by nonlinear regression and were compared to historical values reported in the literature. The predicted mean gastric ion concentration was 23.2 mM (pH 1.6) with the peak time at 12.6 hours (8:30 p.m.), and the half-time for H+ removal from the stomach averaged 1.7 hours. The estimated half-life of gastric food removal was 0.8 hours. The rate constant for normal H+/K+-ATPase degradation was 0.045 h(-1). The pharmacodynamic parameter describing lansoprazole action on gastric acid secretion was the second-order enzyme inactivation constant, which averaged 0.16 microg(-1) x L x h(-1). The parameters obtained for both the baseline and drug treatment data were consistent with the literature and physiologically relevant with the exception of effective food volume, which was large presumably due to buffer effects. The model successfully incorporated the physiological regulation of gastric acid production, the effects of food on gastric acid, and the effects of multiple-dosing regimens of lansoprazole on gastric acid production to give reasonable profiles of gastric pH.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11269565     DOI: 10.1177/00912700122010069

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  8 in total

1.  Utilizing In Vitro Dissolution-Permeation Chamber for the Quantitative Prediction of pH-Dependent Drug-Drug Interactions with Acid-Reducing Agents: a Comparison with Physiologically Based Pharmacokinetic Modeling.

Authors:  Andy Z X Zhu; Ming-Chih David Ho; Christopher K Gemski; Bei-Ching Chuang; Mingxiang Liao; Cindy Q Xia
Journal:  AAPS J       Date:  2016-09-06       Impact factor: 4.009

Review 2.  Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.

Authors:  Vivaswath S Ayyar; William J Jusko
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

3.  Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control.

Authors:  Hongyun Wang; Feng Shao; Xuemei Liu; Wen Xu; Ning Ou; Xianghong Qin; Fang Liu; Xuemei Hou; Haitang Hu; Ji Jiang
Journal:  Br J Clin Pharmacol       Date:  2019-10-15       Impact factor: 4.335

4.  Pharmacokinetics, Pharmacodynamics and Safety of Multiple-Infusion Ilaprazole in Healthy Chinese Subjects.

Authors:  Hongyun Wang; Liwei Lang; Ning Ou; Ruihua Shi; Haitang Hu; Pei Hu; Ji Jiang
Journal:  Clin Drug Investig       Date:  2016-06       Impact factor: 2.859

5.  Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults.

Authors:  Lihua Wu; Jian Liu; Yunliang Zheng; You Zhai; Meihua Lin; Guolan Wu; Duo Lv; Jianzhong Shentu
Journal:  Clin Drug Investig       Date:  2019-10       Impact factor: 2.859

6.  Semi-Mechanism-Based Pharmacokinetic-Toxicodynamic Model of Oxaliplatin-Induced Acute and Chronic Neuropathy.

Authors:  Shinji Kobuchi; Risa Shimizu; And Yukako Ito
Journal:  Pharmaceutics       Date:  2020-02-03       Impact factor: 6.321

7.  Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods.

Authors:  Monica Tang; Kathryn V Blake; John J Lima; Edward B Mougey; James Franciosi; Stephan Schmidt; Md Jobayer Hossain; Marjan Cobbaert; Bernard M Fischer; Jason E Lang
Journal:  Contemp Clin Trials       Date:  2019-01-16       Impact factor: 2.226

8.  Accelerating Development of Benziamidazole-Class Proton Pump Inhibitors: A Mechanism-Based PK/PD Model to Optimize Study Design with Ilaprazole as a Case Drug.

Authors:  Ranran Jia; Fan Zhang; Ni Wu; Wen Xu; Huitao Gao; Bo Liu; Hongyun Wang
Journal:  Pharmaceutics       Date:  2021-03-15       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.